Bedfordshire and Luton Joint Prescribing Committee
Ref: JPC Bulletin 281
Bulletin Date: 19/09/19
Review Date: September 2021
Bulletin 281: Fluticasone furoate/ umeclidinium/ vilanterol 92/55/22 micrograms inhalation powder (Trelegy® Ellipta®) for the treatment of COPD
- The committee agreed to add fluticasone furoate/ umeclidinium / vilanterol (Trelegy ® Ellipta® 92 microgram / 55 microgram / 22 microgram) to the formulary within its licensed indication as a joint 1st-line triple therapy option (ICS / LAMA/ LABA) for the treatment of COPD.